Spurned suitor still chasing elusive Elan takeover deal
The chief executive of Royalty Pharma is still keen to talk to Ireland’s largest indigenous pharma group about making a deal work
Elan puts itself on market as prospects for restructuring plan fade
Review of proxies suggests stalemate after four-month battle for control of company
Irish-based Royalty Pharma are already a major player in field
Founded in 1996, it built a major business by procuring the rights to royalties of some of the major drugs in the market, including Humira, Januvia, Lyrica and Remicade
Royalty cuts acceptance bar for Elan bid to 50%
US firm has raised hostile cash bid for Dublin-based drug maker to $12.50 per share
Elan considered buying Royalty Pharma before becoming its target
Royalty submits its $5.7 billion bid, standing by a reduced price
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices